Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.41 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7260153 | 0.88 | KCNA5 (0.46) | KCNA5KDM4AADRB2HTR1AALDH1A1 | |
| SCHEMBL7254337 | 0.88 | KCNA5 (0.42) | KCNA5KDM4AADRB2HTR1AALDH1A1 | |
| SCHEMBL6874085 | 0.87 | NQO2 (0.51) | ADRB2HTR1AMEN1KMT2ASCN9A | |
| SCHEMBL7257917 | 0.85 | KCNA5 (0.43) | KCNA5KDM4AADRB2HTR1AALDH1A1 | |
| SCHEMBL6871966 | 0.85 | TDP1 (0.49) | ADRB2HTR1A | |
| SCHEMBL11227054 | 0.84 | L3MBTL1 (0.54) | KCNA5KDM4AALDH1A1NPSR1MEN1 | |
| SCHEMBL7260039 | 0.84 | ADRB2 (0.47) | KCNA5KDM4AADRB2HTR1AALDH1A1 | |
| SCHEMBL3417084 | 0.83 | HPGD (0.60) | ALDH1A1NPSR1MEN1KMT2AHPGD | |
| SCHEMBL91198 | 0.83 | ADRB2 (0.46) | KCNA5ADRB2HTR1ASCN9A | |
| SCHEMBL12635254 | 0.83 | ADRB2 (0.40) | KCNA5KDM4AADRB2HTR1ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284655-A1 | LIBRARIES OF HETEROARYL-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CYCLENIUM PHARMA INC. (CA) | 2021-09-16 | — | — | US | disclosed |
| US-10981931-B2 | Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same | CYCLENIUM PHARMA INC. (CA) | 2021-04-20 | — | — | US | disclosed |
| US-20200190083-A1 | LIBRARIES OF PYRIDINE-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CYCLENIUM PHARMA INC. (CA) | 2020-06-18 | — | — | US | disclosed |
| US-20200157116-A1 | LIBRARIES OF HETEROARYL-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CYCLENIUM PHARMA INC. (CA) | 2020-05-21 | — | — | US | disclosed |
| US-10407442-B2 | Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same | CYCLENIUM PHARMA INC. (CA) | 2019-09-10 | — | — | US | disclosed |
| US-20190153620-A1 | LIBRARIES OF DIVERSE MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CYCLENIUM PHARMA INC. (CA) | 2019-05-23 | — | — | US | disclosed |
| WO-2017197488-A1 | LIBRARIES OF DIVERSE MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CYCLENIUM PHARMA INC. (CA) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017049383-A1 | LIBRARIES OF HETEROARYL-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CYCLENIUM PHARMA INC. (CA) | 2017-03-30 | — | — | WO | disclosed |
| EP-2457893-A1 | Intermediates for macrocyclic modulators of the ghrelin receptor | Tranzyme Pharma, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-7491695-B2 | Therapy for endocrime disorders; gastrointestinal disorders; cardiovascular disorders; obesity; central nervous system disorders; antiproliferative agents ; using growth hormone secretagogue receptor | TRANZYME PHARMA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| WO-2006009645-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2003011222-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157116-A1 | LIBRARIES OF HETEROARYL-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | NCOA3, VDR, GRK3 | KCNA5 1164/4885KDM4A 4572/4885ADRB2 610/4885 |
| US-20190153620-A1 | LIBRARIES OF DIVERSE MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | VDR, TRPM8, TRPM7 | KCNA5 901/4885KDM4A 4715/4885ADRB2 1081/4885 |
| US-20210284655-A1 | LIBRARIES OF HETEROARYL-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | NCOA3, VDR, GRK3 | KCNA5 1164/4885KDM4A 4572/4885ADRB2 610/4885 |
| US-10981931-B2 | Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same | NCOA3, VDR, GRK3 | KCNA5 1164/4885KDM4A 4572/4885ADRB2 610/4885 |
| US-20200190083-A1 | LIBRARIES OF PYRIDINE-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | VDR, TRPM8, TRPM7 | KCNA5 605/4885KDM4A 3642/4885ADRB2 1216/4885 |
| US-10407442-B2 | Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same | NCOA3, VDR, GRK3 | KCNA5 1164/4885KDM4A 4572/4885ADRB2 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.